Streamlining MultiPlan Prior Authorization for Pulmonology
Navigating MultiPlan prior authorization for pulmonology services requires precision to ensure timely patient access to critical respiratory care and high-cost therapies.
For revenue cycle directors and prior authorization coordinators, managing the complexities of pulmonology PAs, particularly for high-cost biologics and durable medical equipment, presents significant operational challenges. When dealing with payer plans like MultiPlan, understanding the specific requirements and common denial patterns is essential for maintaining revenue integrity and optimizing patient care pathways.
The Nuances of Pulmonology Prior Authorization with MultiPlan
Pulmonology prior authorizations span a wide range of services, from advanced diagnostic imaging to life-sustaining therapies and specialty medications. For MultiPlan members, these requirements are designed to ensure medical necessity, aligning with their specific benefit designs and formulary structures. This often includes stringent criteria for severe asthma biologics, home oxygen, and pulmonary rehabilitation programs.
High-Volume Pulmonology Services Requiring MultiPlan Prior Authorization
- Asthma biologics (e.g., Dupixent, Nucala, Fasenra, Tezspire)
- Home oxygen and related respiratory equipment (e.g., BiPAP, CPAP)
- Pulmonary function testing (PFTs) in specific contexts
- Certain specialty drugs for conditions like COPD (e.g., Ohtuvayre, Trelegy, Breztri) and IPF (e.g., Esbriet, Ofev)
- Lung transplant evaluations and associated immunosuppression regimens
Navigating MultiPlan's Medical Necessity Criteria for Respiratory Care
Payer plans, including MultiPlan, typically base their medical necessity determinations on established clinical guidelines and internal policies. For pulmonology, this often involves adherence to guidelines such as those published by the ATS, GOLD for COPD, and GINA for asthma. Understanding how MultiPlan interprets and applies these standards, particularly for step-therapy protocols and specific diagnostic thresholds like eosinophil counts for biologics, is critical for successful PA submissions.
Common Denial Factors in MultiPlan Pulmonology Prior Authorizations
Prior authorization denials for pulmonology services with MultiPlan often stem from common issues that can be mitigated with robust documentation and process automation. Frequent reasons include failure to meet step-therapy requirements for asthma biologics, insufficient eosinophil-count thresholds for IL-5 targeting therapies, or inadequate documentation of conservative therapy trials for conditions like IPF prior to requesting antifibrotics.
Optimizing Documentation for MultiPlan Pulmonology Approvals
Accurate and comprehensive documentation is paramount for securing timely approvals from MultiPlan. For asthma biologics, this includes detailed records of eosinophil counts (peripheral or sputum), prior controller therapy at maximum tolerated doses, and a history of exacerbations and severity classification. Klivira's platform automates the extraction and organization of these critical data points from EMRs, aligning them with payer-specific requirements and clinical guidelines.
Streamlining MultiPlan Pulmonology PA Workflows with Klivira
Klivira integrates directly with your EMR to automate the complex MultiPlan prior authorization process for pulmonology services. Our platform incorporates GINA/GOLD/ATS-aware step-therapy logic and automates eosinophil-count documentation, significantly reducing manual effort and improving approval rates for high-volume asthma biologic re-authorizations. This ensures that your team can focus on patient care rather than administrative burdens.
Frequently asked questions
What pulmonology services commonly require prior authorization with MultiPlan?
MultiPlan typically requires prior authorization for high-cost specialty medications like asthma biologics (e.g., Dupixent, Nucala), durable medical equipment such as home oxygen and BiPAP machines, and certain advanced diagnostic procedures or therapies for conditions like IPF and severe asthma maintenance.
How does MultiPlan evaluate medical necessity for asthma biologics?
MultiPlan's evaluation for asthma biologics generally aligns with established clinical guidelines (e.g., GINA). This often involves verifying specific eosinophil-count thresholds, documented trial failures of maximum-dose inhaled corticosteroids (step therapy), and a history of severe exacerbations to confirm medical necessity.
What are common reasons for MultiPlan denying pulmonology prior authorizations?
Common denial reasons include not meeting step-therapy requirements for biologics, eosinophil-count thresholds falling below payer-specified levels, or insufficient documentation of prior conservative therapies for conditions like idiopathic pulmonary fibrosis (IPF). Incomplete or misaligned documentation with MultiPlan's specific criteria is also a frequent cause.
Can Klivira help with re-authorizations for MultiPlan pulmonology cases?
Yes, Klivira's platform is designed to streamline re-authorization workflows for MultiPlan pulmonology cases, particularly for ongoing therapies like asthma biologics. Our system automates the tracking of re-authorization dates and facilitates the collection of updated clinical documentation required for continued approval, minimizing lapses in care.
Does Klivira integrate with my EMR for MultiPlan pulmonology PA submissions?
Yes, Klivira offers robust EMR integration capabilities, including SMART on FHIR, to extract necessary clinical data directly from your system. This enables automated population of MultiPlan prior authorization forms, ensuring data accuracy and reducing manual data entry for pulmonology cases.
Related coverage
Ready to automate prior auth for this plan?
See how Klivira automates prior authorizations for your team.
Request a demo